Rapid Diagnostek

About Rapid Diagnostek

In the world of medical technology, speed and accuracy are paramount. This was the core idea behind Rapid Diagnostek, a company that set out to revolutionize diagnostic testing. Founded in 1986 and later known as Intellignostics, the company, led by President & CEO Harry Norris and VP of Product Development Dr. Peter Schiller, aimed to create a handheld device that could deliver accurate results in just sixty seconds. The business was built on its proprietary IntelliProbe Immunosensor technology. This platform was designed to detect a wide range of biological markers, from viruses and bacteria to hormones and tumor markers, in both human and animal health. The goal was to empower various markets, including healthcare, veterinary medicine, and food safety, with a portable, easy-to-use, and cost-effective diagnostic tool. This would allow for immediate testing outside of traditional laboratory settings. Rapid Diagnostek attracted investor attention, raising a total of $9.93 million over five funding rounds from firms like Peakridge Capital, NEW Capital Fund, and Capital Midwest Fund. The capital was intended to fuel the development and commercialization of their ambitious diagnostic platform. Despite the promising technology and investor backing, the company ultimately faced insurmountable challenges. The journey for Rapid Diagnostek did not lead to an IPO or a major acquisition. Instead, after an asset sale, the venture-backed startup ceased operations. The company is now considered deadpooled, a term for a company that has gone out of business.